12 April 2016 - PHARMAC is seeking feedback on a proposal to list bedaquiline fumarate (Sirturo) and siltuximab (Sylvant) resulting from a provisional agreement between Janssen-Cilag Pty Ltd and PHARMAC.

In summary, this proposal would result in:

• Bedaquiline fumarate being funded in the community and in DHB hospitals for treatment of extensively drug resistant tuberculosis (XDR-TB). Listing in the Pharmaceutical Schedule would occur subject to Medsafe approval of the pharmaceutical
• Siltuximab being funded in the community and in DHB hospitals for treatment of HIV-negative, HHV-8 negative multicentric Castleman’s disease. This listing would occur from 1 June 2016.

For more details, go to: http://www.pharmac.govt.nz/news/consultation-2016-04-12-bedaquiline-siltuximab-rare-disorders/